Evidence map›Paper›PMID 37584526›Full record

ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2023

Clinical Impact of

İpek Yönal-Hindilerden, Ezgi Şahin, Fehmi Hindilerden, Aynur Dağlar-Aday, Meliha Nalçacı

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

İpek Yönal-Hindilerdenİstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, TürkiyeORCID 0000-0003-1353-2367
Ezgi Şahinİstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, TürkiyeORCID 0000-0001-6162-8983
Fehmi HindilerdenUniversity of Health Sciences Türkiye Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Hematology, İstanbul, TürkiyeORCID 0000-0002-6297-9555
Aynur Dağlar-Adayİstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Medical Genetics, İstanbul, TürkiyeORCID 0000-0001-8072-0646
Meliha Nalçacıİstanbul University İstanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, İstanbul, TürkiyeORCID 0000-0002-2555-5024
Istanbul University · TRUniversity of Health Science · KH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The impact of Materials and Methods: A total of 228 patients with Ph-negative MPNs, including 118 with essential thrombocythemia (ET), 84 with primary myelofibrosis (PMF), and 26 with polycythemia vera (PV), were analyzed. The JAK2 MutaScreen assay was used to quantify Results: In PV cases, high Conclusion: Our results suggest that high

Indexed as

Myeloproliferative DisordersPolycythemia VeraPrimary MyelofibrosisThrombocythemia, EssentialAllelesHumansJanus Kinase 2MutationSplenomegalyJanus Kinase 2JAK2 MutaScreen assayJAK2V617F allele burdenPhiladelphia-negative myeloproliferative neoplasms

Identifiers

PMID37584526
PMCPMC10476250
OpenAlexW4385850820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.